On May 19, 2020, Phlow, a U.S.-based, public benefit drug manufacturing corporation, received federal government funding of $354 million for advanced manufacturing of America’s most essential medicines at risk of shortage, including medicines for the COVID-19 pandemic response.

With its strategic partners, Civica Rx, Virginia Commonwealth University’s Medicines for All Institute, and AMPAC Fine Chemicals, Phlow has initiated manufacturing chemical precursor ingredients, active pharmaceutical ingredients (APIs), and finished dosage forms for over a dozen essential medicines to treat hospitalized patients with COVID-19-related illnesses.